BRD4 and neoplasm: In ovarian cancer, targeting CCR2+ TAMs with BRD4 specific inhibitor (ABBV-075) selectively depletes this pro-tumor subset, overcoming adaptive resistance to anti-VEGF therapy while sparing M1-like macrophages (94).